These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 3038453)

  • 21. 3H-cyclosporine internalization and secretion by human fetal pancreatic islets.
    Formby B; Walker L; Peterson CM
    Proc Soc Exp Biol Med; 1988 Oct; 189(1):72-8. PubMed ID: 3054904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Direct effects of cyclosporin A on human pancreatic beta-cells.
    Nielsen JH; Mandrup-Poulsen T; Nerup J
    Diabetes; 1986 Sep; 35(9):1049-52. PubMed ID: 3527825
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclosporin A and islet function.
    Basadonna G; Montorsi F; Kakizaki K; Merrell RC
    Am J Surg; 1988 Sep; 156(3 Pt 1):191-3. PubMed ID: 3048134
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effect of cyclosporin A on glucose-induced insulin secretion by isolated human islets of Langerhans.
    Jutte NH; Heyse P; Bruining GJ; Zeilmaker GH; Weimar W
    Transplant Proc; 1987 Oct; 19(5):4152-3. PubMed ID: 3314005
    [No Abstract]   [Full Text] [Related]  

  • 25. Effect of cyclosporin-A on insulin secretion in vitro.
    Laube F; Hahn HJ
    Horm Metab Res; 1985 Jan; 17(1):43-4. PubMed ID: 3881326
    [No Abstract]   [Full Text] [Related]  

  • 26. Ciamexon-treatment in endocrine ophthalmopathy.
    Utech C; Wulle KG; Pfannenstiel P; Adam W
    Acta Endocrinol Suppl (Copenh); 1987; 281():342-3. PubMed ID: 3303793
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Inhibition of insulin release in vitro mediated by mononuclear cells from diabetic patients treated with cyclosporin A or placebo.
    Debray-Sachs M; Sai P; Feutren G; Lang F; Maugendre D; Boitard C; Hors J; Bach JF
    Diabetes; 1988 Jul; 37(7):873-7. PubMed ID: 3290005
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Influence of the immunomodulating compound BM 12.531 (azimexone) on radioresistance and granulopoietic colony forming units in mice.
    Gassel WD; Laukel H; Braun R; Werner T; Bicker U
    Exp Pathol; 1981; 20(2):105-7. PubMed ID: 7327218
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of BM 12,531 (azimexon) on in vitro lymphocyte and macrophage proliferation.
    Hadden JW; Coffey RG
    Recent Results Cancer Res; 1980; 75():162-4. PubMed ID: 7232828
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence on the formation of unstable haemoglobin by the immunomodulating 2-cyanaziridines azimexone and BM 41.332 in mice.
    Isert B; Mengel K; Bicker U; Friedberg KD
    J Immunopharmacol; 1985; 7(2):179-93. PubMed ID: 4031509
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of the perfluorochemical FC43 on function of isolated islets: a preliminary report.
    Zekorn T; Siebers U; Bretzel RG; Heller S; Meder U; Ruttkay H; Zimmermann U; Federlin K
    Horm Metab Res; 1991 Jun; 23(6):302-3. PubMed ID: 1916646
    [No Abstract]   [Full Text] [Related]  

  • 32. Suppression of pancreatic beta cell function by cyclosporin.
    du Toit DF
    S Afr Med J; 1987 Aug; 72(3):226. PubMed ID: 3299764
    [No Abstract]   [Full Text] [Related]  

  • 33. The influence of cyclosporin A on the vascular permeability of the pancreatic islets and on diabetes induced by multiple low doses of streptozotocin in the mouse.
    Jansson L; Sandler S
    Virchows Arch A Pathol Anat Histopathol; 1988; 412(3):225-30. PubMed ID: 3124343
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Suppression of thymidine incorporation into alloresponding adult peripheral blood leukocytes in vitro by cyclosporine-pretreated human fetal isletlike cell clusters.
    Christiaansen JE; Peterson CM
    Transplantation; 1987 Oct; 44(4):575-7. PubMed ID: 3313847
    [No Abstract]   [Full Text] [Related]  

  • 35. A randomized controlled trial of ciamexon versus placebo in the immunomodulatory treatment of rheumatoid arthritis.
    Baerwald C; Goebel KM; Krause A; Heymanns J
    Arthritis Rheum; 1990 May; 33(5):733-8. PubMed ID: 2189417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glucagon production by cultured pancreatic islets: effects of different culture conditions and media.
    Andersson A; Eriksson U; Ostenson CG
    In Vitro; 1981 May; 17(5):378-84. PubMed ID: 6166539
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vivo immunomodulating properties of two synthetic agents: azimexon and tuftsin.
    Florentin I; Schulz J; Bruley-Rosset M; Kiger N; Martinez J; Mathé G
    Recent Results Cancer Res; 1980; 75():153-61. PubMed ID: 6894500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ciamexone--a new highly selective immunosuppressive compound.
    Bicker U; Pahlke W
    J Immunopharmacol; 1985; 7(1):127-39. PubMed ID: 4008940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reduction of acute toxicity of cyclophosphamide and X-rays by the new immunomodulating compound BM 12.531.
    Bicker U; Friedberg KD; Hebold G; Mengel K
    Experientia; 1979 Oct; 35(10):1361-3. PubMed ID: 499423
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Immunosuppressive agents in endocrine ophthalmopathy. Clinical and experimental studies using cyclosporin and ciamexone].
    Kahaly G
    Fortschr Med; 1990 Aug; 108(23):454. PubMed ID: 2210582
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.